China’s National Health Security Administration said on Sunday that pharmaceutical company Pfizer’s Paxlovid oral drug, which is used to treat Kovid-19, could not be included in the register of medicines in basic medical insurance.
Amid the huge increase in the cases of Kovid-19 in China, the demand for Indian generic medicines has increased significantly here. This information has come out in the media report. Meanwhile, Chinese experts are warning that counterfeit versions of these drugs are being seen in large quantities in the market. China’s National Health Security Administration said on Sunday that pharmaceutical company Pfizer’s Paxlovid oral drug, which is used to treat Kovid-19, could not be included in the register of medicines in basic medical insurance.
Pfizer had quoted the price of Paxlovid oral drug as very high. Due to the acute shortage of Paxlovid, the demand for Indian generic drugs through Chinese e-commerce platforms has increased significantly. At least four generic Covid drugs manufactured in India — Primovir, Paxista, Molnunate and Molnatris — have been listed for sale on Chinese e-commerce platforms in recent weeks, Chinese media company Sixth Tone reported. Primovir and Paxista are both generic versions of paxlovid, while the other two are generic versions of molnipiravir. All four drugs appear to have been approved for emergency use by the Indian authorities, but have not been legalized for use in China.
PressWire18 provides latest news, bollywood news, breaking news hollywood, top tech news, business standard news, indian economy news, world economy news, travel news, mumbai news, latest news mumbai loksabha election 2024, video viral news, delhi news, Only at Only at Presswire18.com
Disclaimer:Prabhasakshi has not edited this news. This news has been published from PTI-language feed.